Actis has bought a life science real estate services company in India and plans to invest $200m (€187.7m) to target assets in the country.
The global investor said it has bought Rx Propellant, a platform focused on providing real estate solutions to tenants in the life sciences and related sectors in India.
Rx Propellant is currently involved in the development and marketing of a number of real estate projects in the design-development stage across Hyderabad and Bangalore.
Actis said it will initially invest $200m into a buy and build programme targeting both greenfield and brownfield assets.
Brian Chinappi, partner and global head of real estate at Actis, said: “The life sciences sector in India is already of global strategic importance, as demonstrated during the Covid-19 pandemic. It is poised for significant growth, owing to a confluence of several factors, both local and global.
”We are excited to be investing in a team that has deep domain expertise and, when combined with Actis’ track record in building sustainability leaders, has the potential to deliver a market-leading enterprise.”
Ashish Singh, partner and head of India and SE Asia Real Estate at Actis, said: “Life sciences corporations have unique requirements and often need customised real estate solutions which are deficient in supply.
”The Rx Propellant management team, with over a decade-long domain experience, looks to fill this gap, and help support India-bound drug discovery and manufacturing programs by providing customised real estate solutions.”
To read the latest edition of the latest IPE Real Assets magazine click here.